3-arylquinazoline derivatives as selective estrogen receptor beta modulators
    7.
    发明授权
    3-arylquinazoline derivatives as selective estrogen receptor beta modulators 有权
    3-芳基喹唑啉衍生物作为选择性雌激素受体β调节剂

    公开(公告)号:US07381730B2

    公开(公告)日:2008-06-03

    申请号:US10387666

    申请日:2003-03-13

    摘要: Novel quinazoline derivatives possessing activity as estrogen receptor beta (ERβ) modulators are provided which have the general formula I wherein X is O or S; A and B are each independently CR′″ or N; R, R′ and R″ are each independently hydrogen, alkyl, benzyl, p-methoxybenzyl, allyl, or Si(R4)3, wherein at least one of R, R′ and R″ is hydrogen; R′″ is hydrogen, halogen, CF3, OR5, S(O)nR6, NR7R8, cycloalkyl or alkyl; R1, R2 and R3 are each independently hydrogen, halogen, CF3, OR5, S(O)nR6, NR7R8, cycloalkyl or alkyl; R4 is a alkyl; R5, R6, R7 and R8 in each functional group are each independently hydrogen, cycloalkyl or alkyl; and n is an integer from 0 to 2. In addition, a method is provided for preventing, inhibiting or treating the progression or onset of pathological conditions associated with the estrogen receptor and to pharmaceutical compositions containing such compounds.

    摘要翻译: 提供具有雌激素受体β(ERbeta)调节剂活性的新型喹唑啉衍生物,其具有通式I,其中X为O或S; A和B各自独立地为CR“或N; R,R'和R“各自独立地为氢,烷基,苄基,对甲氧基苄基,烯丙基或Si(R 4 N 3)3,其中至少一个 R,R'和R“是氢; R“'是氢,卤素,CF 3或OR 5,S(O)n R 6 R 6, NR 7 R 8,环烷基或烷基; R 1,R 2和R 3各自独立地为氢,卤素,CF 3或OR 3, 5,S(O)n R 6,NR 7 R 8,环烷基或烷基 ; R 4是烷基; 各官能团中的R 5,R 6,R 7和R 8分别独立地为氢,环烷基或 烷基; n为0-2的整数。此外,提供了用于预防,抑制或治疗与雌激素受体相关的病理状况的进展或发作的方法以及含有这些化合物的药物组合物。

    C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators
    8.
    发明授权
    C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators 有权
    C-5取代喹唑啉酮衍生物作为选择性雌激素受体β调节剂

    公开(公告)号:US07456188B1

    公开(公告)日:2008-11-25

    申请号:US11411456

    申请日:2006-04-26

    IPC分类号: A61K31/517 C07D239/88

    CPC分类号: C07D239/91 C07D239/93

    摘要: The present application describes compounds according to Formula I, wherein Q, R1, R2 and X are described herein, that are useful as Estrogen Receptor Beta (ERβ) modulators. Additionally, the present application describes pharmaceutical compositions containing the compounds according to Formula I and optionally additional therapeutic agents. Finally, the present application describes methods utilizing the compounds according to Formula I for modulating the function of ERβ in the treatment of diseases and disorders associated with ERβ such as, for example, bone disorders; cardiovascular diseases; hypercholesterolemia; hypertriglyceridemia; vasomotor disorders; urogenital disorders; prostatic hypertrophy; endometrial hyperplasia; cancer and central nervous system disorders, such as, neurodegenerative disorders.

    摘要翻译: 本申请描述了根据式I的化合物,其中Q,R 1,R 2和X在本文中描述,其可用作雌激素受体β(ERβ)调节剂。 此外,本申请描述了含有根据式I的化合物和任选的另外的治疗剂的药物组合物。 最后,本申请描述了利用式I化合物调节ERbeta在治疗与ERBeta相关的疾病和病症(例如骨病)中的功能的方法; 心血管疾病; 高胆固醇血症 高甘油三酯血症 血管舒缩障碍 泌尿生殖系统疾病 前列腺肥大; 子宫内膜增生; 癌症和中枢神经系统疾病,如神经变性疾病。

    3-aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators
    9.
    发明授权
    3-aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators 有权
    3-芳基 - 羟基苯并恶嗪和3,4-二氢-3-芳基 - 羟基苯并恶嗪作为选择性雌激素受体β调节剂

    公开(公告)号:US07015219B2

    公开(公告)日:2006-03-21

    申请号:US10322689

    申请日:2002-12-18

    CPC分类号: C07D265/36

    摘要: Substituted benzoxazine and 3,4-dihydrobenzoxazine derivatives possessing activity as estrogen receptor beta (ERβ) modulators are provided which have the structure of formula I wherein the substitutents are as described herein. In addition, a method is provided for preventing, inhibiting or treating the progression or onset of pathological conditions associated with the estrogen receptor and to pharmaceutical compositions containing such compounds.

    摘要翻译: 提供具有作为雌激素受体β(ERbeta)调节剂的活性的取代的苯并恶嗪和3,4-二氢苯并恶嗪衍生物,其具有式I的结构,其中取代基如本文所述。 此外,提供了一种用于预防,抑制或治疗与雌激素受体相关的病理状况的进展或发作的方法以及含有这些化合物的药物组合物。